Zai Lab Limited Stock Price, News & Analysis

Zai Lab Limited (NASDAQ: ZLAB) reported strong financial performance for 2020, with revenues increasing to $49 million from $13 million in 2019, driven by significant sales of ZEJULA and Optune. The company successfully launched ZEJULA and Optune in China and submitted NDAs for QINLOCK and NUZYRA. Zai Lab plans to launch QINLOCK and NUZYRA in 2021 and expand its pipeline with new partnerships and product candidates. Despite a net loss of $268.9 million, cash reserves grew to $1.19 billion, indicating robust financial health.

Zai Lab Limited (NASDAQ: ZLAB) announced it will report financial results for the year ended December 31, 2020, on March 1, 2021, before the U.S. market opens. The company will host a conference call and webcast at 8:00 a.m. ET on the same day to discuss these results and provide a corporate update. Zai Lab is focused on developing innovative biopharmaceuticals for cancer and autoimmune diseases, aiming to meet significant medical needs in large markets.

Zai Lab Limited (NASDAQ: ZLAB) announced participation in two upcoming virtual investor conferences in February 2021. The Guggenheim Healthcare Talks 2021 Oncology Day fireside chat is scheduled for February 11 at 12:00 p.m. ET, and the 2021 SVB Leerink Global Healthcare Conference presentation will occur on February 26 at 8:00 a.m. ET. A live webcast of the latter will be accessible under the 'Events & Presentations' section of Zai Lab's website, with an archived replay available for 90 days post-event. Zai Lab focuses on innovative treatments for significant medical needs globally.

Zai Lab has secured exclusive rights to develop and commercialize TPX-0022, a MET/SRC/CSF1R inhibitor from Turning Point Therapeutics, in Greater China. This collaboration involves a $25 million upfront payment to Turning Point, with potential milestone payments and royalties totaling approximately $336 million. Zai Lab already holds rights to another Turning Point drug, repotrectinib. The partnership aims to target MET-driven cancers more effectively in a region with high prevalence, with initial studies showing promising safety and efficacy data for TPX-0022.

argenx and Zai Lab have announced an exclusive agreement for the development and commercialization of efgartigimod in Greater China. This collaboration enables argenx to expand its global reach and accelerate clinical development of autoimmune treatments. argenx will receive $175 million, including $75 million in Zai Lab equity and milestone payments. Efgartigimod targets conditions such as myasthenia gravis and has significant potential for changing treatment paradigms. Zai Lab will lead patient recruitment for global trials, enhancing access to this promising therapy for Chinese patients.

Zai Lab (NASDAQ: ZLAB) announced that Dr. Samantha Du will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 11:40 a.m. EST. The live presentation can be accessed through the Investor Relations section on their website, with an archived replay available for 90 days post-event.

Zai Lab focuses on developing transformative therapies for cancer, infectious, and autoimmune diseases, aiming to meet significant medical needs globally. The company partners with leading biopharmaceutical firms to expand its innovative product pipeline.

Zai Lab Limited (NASDAQ: ZLAB) announced that its drug ZEJULA (niraparib) has been included in China's National Reimbursement Drug List by the NHSA. This designation allows ZEJULA to be more accessible as a maintenance therapy for adult patients with recurrent ovarian cancer responding to platinum-based chemotherapy. Dr. Samantha Du emphasized the importance of this inclusion in achieving patient access, while William Liang noted ZEJULA's unique clinical value in China. Ovarian cancer remains a significant health concern, with over 52,000 new cases reported annually.

Zai Lab Limited (NASDAQ: ZLAB) has entered an exclusive license agreement with Cullinan Oncology for CLN-081, an EGFR inhibitor targeting exon 20 insertion mutations, in Greater China. Cullinan will receive $20 million upfront and has the potential to earn up to $211 million in milestone payments and royalties based on sales. This collaboration aims to address high unmet medical needs in lung cancer treatment in China. CLN-081 is currently in a Phase 1/2a trial for NSCLC patients who have previously undergone treatment.

Zai Lab Limited (NASDAQ: ZLAB) announced that the FDA has approved MARGENZA (margetuximab-cmkb) for the treatment of adult patients with metastatic HER2-positive breast cancer, following two or more anti-HER2 regimens. In a Phase 3 trial, MARGENZA demonstrated a 24% reduction in disease progression risk compared to trastuzumab with chemotherapy. The product is set for U.S. launch in March 2021. MARGENZA is also being developed for advanced gastric cancer. Notably, it presents adverse reactions like fatigue (57%) and nausea (33%), with a BOXED WARNING for left ventricular dysfunction.